The Japan RUO immunoassay market is expected to grow at a CAGR of 13.94% from 2025 to 2030.
Japan's RUO (research use only) immunoassay market, has been witnessing notable growth due to several factors such as the world's fastest aging population, leading to a rise in chronic diseases like diabetes, cancer, autoimmune disorders, etc. These shifts in demographics are occurring as the population aged 65 and above experiences unprecedented growth. The proportion of Japan's elderly population, representing a percentage of the total population, witnessed a gradual increase, reaching 28.56% in 2020, 28.86% in 2021, and 29.00% in 2022. The RUO immunoassay is an invaluable tool for research to diagnose and treat this growing chronic disease ailment in the population.
Further major developments such as Sysmex Corporation and Fujirebio Holdings, Inc. announced an Agreement in October 2023, for Business Collaboration to enhance their collaboration in various areas including research and development, production, clinical development, and sales-marketing within the immunoassay field. Additionally, they have agreed on a supply agreement for reagent raw materials specifically for immunoassay applications. Both companies will leverage their expertise and capabilities in immunoassay which would expedite their global growth and contribute significantly to advancing this field of diagnostics.
Technological advancements are playing an important role in the growth prospects of Japan's RUO immunoassay market. In November 2023, JSR Life Sciences Company announced the release of an automated mono-test chemiluminescence immunoassay (CLIA) analyzer “istar 500”. Its compact design, coupled with highly sensitive CLIA technology, makes it an option for emergency diagnostics or small- to medium-sized laboratories seeking precise testing outcomes. This CLIA analyzer provides a comprehensive array of testing parameters encompassing cardiac markers, reproductive health, liver function, tumor markers, and autoimmunity.
With the advancement of ultrasensitive technologies, the demand is increasing particularly in the neurology infectious disease sector, and oncology testing. The higher sensitivity enables, the discovery of new markers at lower levels in all fields, detection, and diagnosis,
Fluxus has been developing an Ultrasensitive Detection system much before. However, since the acquisition of it by Fujirebio HD in 2022, the development of a benchtop RUO analyzer and reagents has been accelerated and is scheduled for launch in 2024. Fujirebio is engaging in discussions with several companies regarding the licensing-out of this technology and its components. Their 15% base revenue spent on R&D activities focuses on immunoassays. Advancements in immunoassay technologies are making RUO assays more sensitive, specific, and user-friendly.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Growth Rate | CAGR of 13.94% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Forecast Unit (Value) | USD Billion |
| Segmentation |
|
| Geographical Segmentation | Kanto, Kansai, Chubu, Others |
| List of Major Companies in the Japan RUO Immunoassay Market | |
| Customization Scope | Free report customization with purchase |
Japan RUO Immunoassay Market Segmentation
By Product Type
By Sample Type
By Application
By End-User
By Region